Anupama Kumar

@MMRFTeam4Cures @TomBmt133 @myelomawolf @DarrenPanMD @anupamakumar05 @apwiita what a great cause, event, and team!

Thanks @AjaiChari for leading new Bridging Gaps recs for myeloma #MMsm, now in @AjHematology! Intentional focus on what makes common sense based on current data, even if not in orig trials. E.g. 1️⃣ 1x/wk Velcade 2️⃣ MRD-guided len 🛑 as option 3️⃣ IVIG PPx & bsAbs Worth a read!

Polling question from @OncLine® Bridging the Gaps: Leukemia, Lymphoma, & Multiple #Myeloma meeting happening now (February 24-25, 2026). How close do you think we are to the cure for multiple myeloma?

Awesome job by @UCSFCancer @Kevin_Reyes650 med student extraordinaire and senior author @AlfredChung11 on this paper - #ASH22 updated data from #IMS22. In short, old lines (including Tx disease was once refractory to) are reasonable to recycle after BCMA CAR-T failure!

Outstanding presentation by @AlfredChung11 on MRD dynamics in Auriga study showing benefit of daratumumab in deepening and sustained responses.

🩸 Inside Insights | Expert commentary from a leading clinician in hematologic malignancies. We asked Dr. Anupama Kumar to share her perspective from inside the room at Great Debates in Hematologic Malignancies. Her key takeaways on Dr. Andrew Cowans's Talk: More is Better! Incorporating Quadruplets into Frontline Therapy for Myeloma " - Quadruplet therapy has been established as standard of care for fit, transplant eligible patients (PERSEUS, IsKIA, etc), and now emerging trials have demonstrated benefit of quadruplet therapy in transplant ineligible patients as well (IMROZ, CEPHEUS, BENEFIT) - The MIDAS trial uses MRD negativity to risk stratify patients into different consolidation arms (ASCT vs IsaKRd maintenance if MRD negativity; tandem vs single transplant if MRD+), and will help guide future decision making of omitting transplant in MRD negative patients - Future studies need to fill gaps for high risk populations (ultra-high risk MM, plasma cell leukemia and functional high risk) and to help answer questions about MRD guided treatment de-escalation" - Anupama Kumar #GDHEM #GreatDebates #Hematology #InsideInsights

🩸 Inside Insights | Expert commentary from a leading clinician in hematologic malignancies. We asked Dr. Andrew Cowan to share his perspective from inside the room at Great Debates in Hematologic Malignancies. His key takeaways on Dr. Murali Janakiram and Dr. Anupama Kumar's debate: Should All Patients with High-Risk Smoldering Myeloma Be Treated? Yes vs No "Key highlights: 1. Dr Janakiram showed us compelling data arguing for early intervention with a CD38 antibody in high risk SMM, based on the results of the AQUILA trial. Most compelling of all, is the overall survival benefit. 2. However, Dr Kumar presented sound counterarguments, arguing that our models do not capture dynamic risk assessment, and that eventually we arrive on a more accurate classification of precursor conditions that may alter how we treat these conditions, in general." - Andrew Cowan #GDHEM #GreatDebates #Hematology #InsideInsights @JanakiramMurali

Looking forward to this! We don't talk enough about palliative care co-management in myeloma, but it will be front & center at this @IMFmyeloma workshop for #MMsm patients in August. Good to see @anupamakumar05 @IMFsupport #andrewcowan and many more speaking as well!

Delayed cart neurotox -likely 4 risk factors demographics, disease burden, high grade crs/icans, peak CAR expansion. However rare so requires continued international collaborations- outstanding work by Dr Kumar and global contributors!

@AjaiChari Thank you to our collaboraters! @YiLinMDPhD @AlbertYunes @myeloma_mogul @paurotero @sridevirajeeve @H_Einsele @DonkNiels @jmartinezlo @BiranNoa @fdezdelarrea @End_myeloma @Ahmed_Abdelhak_ @hhashmi87 @apwiita @comebestsharon @Ccostello7 @TomBmt133 and others!

Delayed neurotoxicity poster with my mentor @AjaiChari

@MeeraMohanMD @Hemobuddy Adding first author @anupamakumar05 to provide some clarity.

@AjaiChari @MeeraMohanMD @Hemobuddy Thanks all for the interest. the registry is only of CAR-T toxicities (n=52), of which there were 16 PD, 37 CN palsies, 4 GBS/neuropathy. We are working with centers who contributed cases to determine total denominator. % are not of all pts who had CAR-T

Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry N=52 (92% cilta-cel 4% ide-cel) 16 PD & 37 CN palsies (4 cases of PN/GBS) 15% in </=1 LOT (7 CN and 1 PD) Is Neurotox really driven by disease burden ? @AjaiChari #mmsm #ASH2024

@andrew02114 @MeeraMohanMD @AjaiChari Thanks all for the interest. the registry is only of CAR-T toxicities (n=52), of which there were 16 PD, 37 CN palsies, 4 GBS/neuropathy. We are working with centers who contributed cases to determine total denominator. % are not of all pts who had CAR-T

@MeeraMohanMD @AjaiChari It would be interesting to know the number of patients in the registry overall to know the percentage of patients affected by delayed neurotoxicity. ASH abstract by @anupamakumar05 ash.confex.com/ash/2024/webpr…

Cinco de Myeloma (observed)! ! Love celebrating with my @UCSFCancer family! @SandyWong02111 @AjaiChari @TomBmt133 @myelomawolf @AlfredChung11

Now at @UCSFDOM Grand Rounds @AjaiChari discussing the vexing problem of Parkinsonism arising after BCMA-targeted CAR-T therapies for #myeloma with @UCSFCancer experts including @anupamakumar05 characterizing the incidence and prognosis in our large treated population. #Tcellrx

New preprint‼️ While BCMA #CART are amazing for #myeloma, pts with high-risk disease relapse sooner. We show CD70 is a novel CAR target enriched in #HRMM and use structure-guided design to optimize anti-CD70 CAR with enhanced in vivo expansion. Thread👇biorxiv.org/content/10.110…

Please join us in welcoming our newest member of the UCSF Myeloma Team - Dr. Anupama Kumar - with interests in CART and bispecific therapy - WELCOME DAY1!!!